Though Active on RINm5F Insulinoma Cells and Cultured Pancreatic Islets, Recombinant IL-22 Fails to Modulate Cytotoxicity and Disease in a Protocol of Streptozotocin-Induced Experimental Diabetes.

Berner, Anika; Bachmann, Malte; Bender, Christine; Pfeilschifter, Josef; Christen, Urs; Mühl, Heiko

Berner, Anika; Bachmann, Malte; Bender, Christine; Pfeilschifter, Josef; Christen, Urs; Mühl, Heiko.

Afiliação

Berner A; Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt Frankfurt am Main, Germany.
Bachmann M; Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt Frankfurt am Main, Germany.
Bender C; Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt Frankfurt am Main, Germany.
Pfeilschifter J; Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt Frankfurt am Main, Germany.
Christen U; Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt Frankfurt am Main, Germany.
Mühl H; Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt Frankfurt am Main, Germany.

Front Pharmacol ; 6: 317, 2015.

Article em En | MEDLINE | ID: mdl-26793108

Palavras-chave

IL-22; RINm5F cells; STAT3 transcription factor; streptozotocin-diabetes; tissue protection; tissue regeneration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google